SLDB Earnings & Financial Statements
Solid Biosciences Inc.
$5.47
-$0.36(-6.10%)
33
Overall
60
Value
18
Tech
21
Quality
Market Cap
$585.99M
Volume
2.38M
52W Range
$3.79 - $11.45
Target Price
$18.62
SLDB earnings and financial statements: Solid Biosciences Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
SLDB Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | $963.0K | $1.09M | $8.09M | $13.62M |
| Cost of revenue | - | - | - | $1.47M | $777.0K |
| Operating income | -$179.21M | -$129.73M | -$104.25M | -$106.45M | -$72.25M |
| EBITDA | -$172.89M | -$121.90M | -$92.99M | -$96.87M | -$69.29M |
| Net income | -$174.32M | -$124.70M | -$96.02M | -$85.98M | -$72.19M |
| EPS (diluted) | $-1.99 | $-3.06 | $-4.83 | $-10.10 | $-10.20 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $232.54M | $188.66M | $164.94M | $260.25M | $232.38M |
| Total liabilities | $52.53M | $51.42M | $38.46M | $48.59M | $24.17M |
| Shareholders’ equity | $180.01M | $137.25M | $126.48M | $211.67M | $208.21M |
| Cash and equivalents | $59.90M | $80.23M | $74.02M | $155.38M | $119.14M |
| Long-term debt | $19.06M | $21.16M | $23.94M | $25.98M | $275.0K |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$156.30M | -$100.01M | -$94.18M | -$97.98M | -$77.76M |
| Capital expenditure | -$1.07M | -$649.0K | -$1.51M | -$3.02M | -$1.28M |
| Free cash flow | -$157.45M | -$100.67M | -$95.69M | -$100.99M | -$79.05M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SLDB | $5.47 | -6.1% | 2.38M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |